Advertisement

Topics

Zymeworks Presents Preclinical Data at the Annual Meeting of the American Association for Cancer Research

05:00 EDT 17 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Highlights ZW49, its HER2-Targeted Bispecific Antibody Drug Conjugate and Novel ZymeLink™ Platform Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today ...

Other Sources for this Article

Zymeworks Inc.
Investor Inquiries:
Ryan Dercho, Ph.D., 604-678-1388
ir@zymeworks.com
or
Media Inquiries:
Angela Bitting, 925-202-6211
a.bitting@comcast.net

NEXT ARTICLE

More From BioPortfolio on "Zymeworks Presents Preclinical Data at the Annual Meeting of the American Association for Cancer Research"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...